As summarized in Table 1, when the five specimen grades (i.e, chronic cervicitis, CIN-I, CIN-II, CIN-III, and cervical cancer) were compared with the frequency of moderate and strong staining, the TGFBR2 expression was found to gradually decrease in the following order: chronic cervicitis (5/11, 45.5%) >CIN-I (14/51, 27.4%) >CIN-II (4/19, 21.1%) >CIN-III (2/27, 7.4%) >cervical cancer (5/164, 3.0%) (p = 0.000, p < 0.05). The gene discussed is TGFBR2; the disease is uterine cervix carcinoma in situ.